Search ARM

Perspectives on Cell & Gene Therapy Development, Manufacturing, and Commercialization In Japan



The Alliance for Regenerative Medicine (ARM) and the Forum for Innovative Regenerative Medicine (FIRM) jointly undertook this study to better understand the gap in available cell and gene therapies in Japan as compared to the United States and the European Union. The study surveyed and interviewed Western pharmaceutical, biotech, and CDMO executives to understand perceived barriers to CGT development, manufacturing, and commercialization in Japan.

Download PDF